Clinical Trial Evaluation Guide: Assessing Candidacy and Risk as an APOE ε4 Carrier

Practical Guide · Trial Assessment

This resource was originally promised as a list of current trials enrolling APOE ε4 carriers, with sites near you. It is not that, deliberately. Any list of open studies goes stale within weeks — enrollment status changes constantly, sites open and close, and a page claiming to be current would be quietly wrong most of the time.

What does not go stale is knowing how to evaluate a trial and your own candidacy for it. That turns out to be where carriers most often go wrong, and the stakes are higher than most realize: for an ε4 carrier considering an anti-amyloid study, genotype affects safety, not merely eligibility.

In CLARITY AD, 1,795 participants with early Alzheimer’s disease received lecanemab or placebo over 18 months. Treatment slowed decline on the Clinical Dementia Rating–Sum of Boxes by 0.45 points (95% CI −0.67 to −0.23; P<0.001). It also produced amyloid-related imaging abnormalities with edema or effusion in 12.6% of participants and infusion-related reactions in 26.4%.1 Those are the headline safety figures, and they are averages across a mixed-genotype population.

What follows covers how to search the registry properly, the four eligibility criteria that disqualify most carriers who apply, the genotype-specific safety question, and what to ask a study coordinator before you consent to anything.